Abivax Sa Quick Ratio (ABVX) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Abivax Sa  (NASDAQ: ABVX)

Abivax Sa's Quick Ratio

ABVX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Quick Ratio deteriorated to 8.2 above company average Quick Ratio.

Within Major Pharmaceutical Preparations industry 114 other companies have achieved higher Quick Ratio than Abivax Sa in fourth quarter 2025. While Quick Ratio total ranking has improved so far during the Q4 2025 to 430, from total ranking in the third quarter 2025 at 1439.

Explain Quick Ratio?
How much Cash & cash equivalents ABVX´s has?
What are ABVX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ABVX Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change -32.96 % -32.96 % -32.96 % -32.96 % 34.2 %
Y / Y Cash & cash equivalent Change 258.26 % 328.42 % 258.26 % 258.26 % -42.76 %
Quick Ratio MRQ 8.2 9.8 8.2 8.2 1.53
ABVX's Total Ranking # 430 # 1439 # # #
Seq. Current Liabilities Change 0 % 0 % 0 % -32.96 % 0 %
Seq. Cash & cash equivalent Change -16.38 % 19.58 % 0 % 258.26 % 0 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 115
Healthcare Sector # 179
Overall Market # 430


Quick Ratio Statistics
High Average Low
8.2 4.44 1.53
(Dec 31 2025)   (Dec 31 2024)




Financial Statements
Abivax Sa's Current Liabilities $ 71 Millions Visit ABVX's Balance sheet
Abivax Sa's Cash & cash equivalent $ 579 Millions Visit ABVX's Balance sheet
Source of ABVX's Sales Visit ABVX's Sales by Geography


Cumulative Abivax Sa's Quick Ratio

ABVX's Quick Ratio for the trailling 12 Months

ABVX Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth -32.96 % -19.59 % -4.28 % 13.45 % 34.2 %
Y / Y Cash & cash equivalent TTM Growth 275.8 % 162.26 % 66.83 % 5.48 % -42.76 %
Quick Ratio TTM 8.6 6.34 4.21 2.75 1.53
Total Ranking TTM # 2820 # 3491 # # #
Seq. Current Liabilities TTM Growth -10.94 % -9.86 % -8.98 % -8.24 % 6.81 %
Seq. Cash & cash equivalent TTM Growth 20.74 % 35.83 % 39.23 % 64.56 % -15.73 %

Quick ratio ranking by company, industry and sector >> Back to ABVX Financial Strength Comparisons >> Go to Compare ABVX Quick Ratio to its Competitors

On the trailing twelve months basis ABVX Cash & cash equivalent more than doubled by 258.26 % in Q4 2025 year on year, while Current Liabilities remained unchanged to $71 millions, this led to increase in in Abivax Sa's Quick Ratio to 8.6, above ABVX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 369 other companies have achieved higher Quick Ratio than Abivax Sa. While Quick Ratio overall ranking has improved so far to 2820, from total ranking during the twelve months ending third quarter 2025 at 3491.

Explain Quick Ratio?
How much Cash & cash equivalents ABVX´s has?
What are ABVX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 370
Healthcare Sector # 763
Within the Market # 2820


trailing twelve months Quick Ratio Statistics
High Average Low
3.6 3.6 3.6
(Dec 31 2023)  




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Sagimet Biosciences inc   22.52 $ 113.124  Millions$ 5.023  Millions
Dyne Therapeutics Inc   21.94 $ 1,110.562  Millions$ 50.625  Millions
Arca Biopharma Inc  21.92 $ 337.044  Millions$ 15.374  Millions
Aprea Therapeutics Inc   20.46 $ 14.599  Millions$ 0.714  Millions
Spyre Therapeutics Inc   20.40 $ 1,197.428  Millions$ 58.685  Millions
Jade Biosciences Inc   20.33 $ 336.158  Millions$ 16.539  Millions
Siga Technologies Inc  19.99 $ 154.966  Millions$ 7.753  Millions
Trevi Therapeutics Inc   19.94 $ 188.260  Millions$ 9.442  Millions
Edgewise Therapeutics inc   19.37 $ 530.109  Millions$ 27.370  Millions
Maplight Therapeutics Inc   18.80 $ 305.103  Millions$ 16.229  Millions
Kezar Life Sciences Inc   16.92 $ 71.878  Millions$ 4.248  Millions
Stoke Therapeutics Inc   16.90 $ 284.670  Millions$ 16.840  Millions
Design Therapeutics Inc   16.84 $ 219.845  Millions$ 13.055  Millions
Neurogene Inc   16.39 $ 269.013  Millions$ 16.411  Millions
Xbiotech Inc   15.83 $ 125.551  Millions$ 7.929  Millions
Tango Therapeutics Inc   15.83 $ 343.138  Millions$ 21.679  Millions
Mira Pharmaceuticals Inc   15.71 $ 11.030  Millions$ 0.702  Millions
Phio Pharmaceuticals Corp  15.69 $ 21.031  Millions$ 1.340  Millions
Alto Neuroscience Inc   15.58 $ 176.484  Millions$ 11.325  Millions
Veradermics Inc  15.50 $ 141.862  Millions$ 9.152  Millions
Ocular Therapeutix Inc   15.36 $ 737.060  Millions$ 47.989  Millions
Nuvalent Inc   15.05 $ 1,371.952  Millions$ 91.171  Millions
Mereo Biopharma Group Plc  14.66 $ 41.387  Millions$ 2.824  Millions
Bioharvest Sciences Inc   14.57 $ 46.050  Millions$ 3.160  Millions
Immunome Inc   14.55 $ 654.782  Millions$ 44.990  Millions
Eupraxia Pharmaceuticals Inc   14.51 $ 80.563  Millions$ 5.551  Millions
Climb Bio Inc   14.47 $ 101.080  Millions$ 6.984  Millions
Synlogic Inc   14.41 $ 14.668  Millions$ 1.018  Millions
Cervomed Inc   14.35 $ 20.864  Millions$ 1.454  Millions
Bicara Therapeutics Inc   14.33 $ 414.801  Millions$ 28.949  Millions

Date modified: 2026-09-08T15:31:11+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.